

Marc Suárez-Calvet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3829043/publications.pdf>

Version: 2024-02-01

140
papers

7,454
citations

71061

41
h-index

60583

81
g-index

158
all docs

158
docs citations

158
times ranked

9378
citing authors

#	ARTICLE	IF	CITATIONS
1	Genotypic effects of APOE- β 4 on resting-state connectivity in cognitively intact individuals support functional brain compensation. <i>Cerebral Cortex</i> , 2023, 33, 2748-2760.	1.6	5
2	CSF p-tau231: A biomarker for early preclinical Alzheimer?. <i>EBioMedicine</i> , 2022, 77, 103936.	2.7	2
3	Age, sex and APOE- β 4 modify the balance between soluble and fibrillar β -amyloid in non-demented individuals: topographical patterns across two independent cohorts. <i>Molecular Psychiatry</i> , 2022, 27, 2010-2018.	4.1	9
4	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. <i>Lancet Neurology</i> , The, 2022, 21, 329-341.	4.9	72
5	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879.	0.4	26
6	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. <i>Nature Reviews Neurology</i> , 2022, 18, 400-418.	4.9	99
7	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. <i>PLoS ONE</i> , 2022, 17, e0267298.	1.1	9
8	Brain alterations in the early Alzheimer's continuum with amyloid- β , tau, glial and neurodegeneration CSF markers. <i>Brain Communications</i> , 2022, 4, .	1.5	12
9	Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer's continuum. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4567-4579.	3.3	16
10	The BDNF Val66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 614-628.	4.1	61
11	Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. <i>Brain</i> , 2021, 144, 325-339.	3.7	124
12	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. <i>Molecular Psychiatry</i> , 2021, 26, 429-442.	4.1	186
13	Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12168.	1.2	52
14	Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 17.	3.0	35
15	Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 46.	3.0	9
16	Cerebral amyloid- β load is associated with neurodegeneration and gliosis: Mediation by p-tau and interactions with risk factors early in the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, 788-800.	0.4	14
17	DHA intake relates to better cerebrovascular and neurodegeneration neuroimaging phenotypes in middle-aged adults at increased genetic risk of Alzheimer disease. <i>American Journal of Clinical Nutrition</i> , 2021, 113, 1627-1635.	2.2	17
18	Race and Alzheimer Disease Biomarkers. <i>Neurology: Genetics</i> , 2021, 7, e574.	0.9	6

#	ARTICLE	IF	CITATIONS
19	CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia. <i>Neurobiology of Aging</i> , 2021, 103, 158.e1-158.e5.	1.5	8
20	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 396.	4.5	146
21	Cognitively unimpaired individuals with a low burden of A β 2 pathology have a distinct CSF biomarker profile. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 134.	3.0	8
22	Amyloid- β 2 positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume. <i>Neurobiology of Aging</i> , 2021, 104, 24-31.	1.5	13
23	Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer's continuum. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 135.	3.0	30
24	Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 119-128.	1.2	3
25	CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET. <i>Neurology</i> , 2021, 97, e2065-e2078.	1.5	40
26	Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. <i>Environment International</i> , 2021, 157, 106864.	4.8	40
27	Comparative Analysis of Different Definitions of Amyloid- β 2 Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer. <i>Journal of Prevention of Alzheimer's Disease</i> , 2021, 8, 1-10.	1.5	9
28	P-tau235: a novel biomarker for staging preclinical Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2021, 13, e15098.	3.3	30
29	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. <i>JAMA Neurology</i> , 2021, 78, 1471.	4.5	204
30	Higher levels of the astrocytic marker CSF YKL40 are associated with better memory performance only in amyloid- β 2 positive individuals with subjective cognitive decline. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
31	Brain structural alterations in cognitively unimpaired individuals with discordant amyloid- β 2 PET and CSF A β 42 status: Findings using machine learning. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
32	Machine learning on combined neuroimaging and plasma biomarkers for triaging participants of secondary prevention trials in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
33	Imaging neurodegeneration markers are associated with multiple pathophysiological mechanisms in the early stages of the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
34	Subjective cognitive decline is associated with higher anxiety and depression during the COVID-19 related confinement. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
35	Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
36	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	7

#	ARTICLE	IF	CITATIONS
37	Synergistic effects of CSF A β 42 and p τ on functional resting-state connectivity in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
38	Cross-sectional associations between sleep quality reports and core Alzheimer's disease biomarkers in cognitively unimpaired adults from the European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS). <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
39	Distinctive effect of biological sex in AD-related CSF and plasma biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
40	Data-driven approach for early detection of pathological pathways in middle-aged adults with family history of sporadic Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
41	Structural, metabolic and cognitive characteristics of cognitively unimpaired subjects with mismatching β -amyloid biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
42	Associations between iron deposition in the brain and grey matter volumes in cognitively unimpaired adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
43	Association of body mass index with brain structure and biomarkers of inflammation in cognitively unimpaired middle-aged adults with and without evidence of β -amyloid pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
44	Sex, caregiver status and amyloid positivity predict increased anxiety and depression during the COVID-19-related confinement. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
45	Impaired default mode network along with increased functional connectivity of the medial temporal lobe as a function of CSF p τ /Ab42 ratio in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
46	Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals. <i>Brain Imaging and Behavior</i> , 2020, 14, 2012-2023.	1.1	40
47	Association between insomnia and cognitive performance, gray matter volume, and white matter microstructure in cognitively unimpaired adults. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 4.	3.0	53
48	White matter hyperintensities mediate gray matter volume and processing speed relationship in cognitively unimpaired participants. <i>Human Brain Mapping</i> , 2020, 41, 1309-1322.	1.9	27
49	Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. <i>Molecular Neurodegeneration</i> , 2020, 15, 57.	4.4	33
50	Sex Differences of Longitudinal Brain Changes in Cognitively Unimpaired Adults. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1413-1422.	1.2	4
51	Association of years to parent's sporadic onset and risk factors with neural integrity and Alzheimer biomarkers. <i>Neurology</i> , 2020, 95, e2065-e2074.	1.5	3
52	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Acta Neuropathologica</i> , 2020, 140, 267-278.	3.9	209
53	Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation. <i>EMBO Molecular Medicine</i> , 2020, 12, e12308.	3.3	73
54	Effect of BDNF Val66Met on hippocampal subfields volumes and compensatory interaction with APOE- ϵ 4 in middle-age cognitively unimpaired individuals from the ALFA study. <i>Brain Structure and Function</i> , 2020, 225, 2331-2345.	1.2	5

#	ARTICLE	IF	CITATIONS
55	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in A β pathology are detected. <i>EMBO Molecular Medicine</i> , 2020, 12, e12921.	3.3	202
56	Protective genetic variants in the MS4A gene cluster modulate microglial activity. <i>Alzheimer's and Dementia</i> , 2020, 16, e039431.	0.4	1
57	Impact of the APOE gene on amyloid deposition in participants with abnormal soluble amyloid levels. <i>Alzheimer's and Dementia</i> , 2020, 16, e042955.	0.4	0
58	Amyloid β , tau, synaptic dysfunction, neurodegeneration, glial and vascular biomarkers in the preclinical stage of the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044444.	0.4	0
59	Emerging beta-amyloid pathology is associated with tau, synaptic, neurodegeneration and gray matter volume differences. <i>Alzheimer's and Dementia</i> , 2020, 16, e044466.	0.4	1
60	Genetically predicted telomere length and Alzheimer's disease endophenotypes: A Mendelian randomization study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044720.	0.4	0
61	The effect of physical activity on CSF biomarkers of Alzheimer's disease differs between men and women. <i>Alzheimer's and Dementia</i> , 2020, 16, e044722.	0.4	0
62	Multiple biological pathways associate with cerebral amyloid load in the early Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044733.	0.4	0
63	Higher frontoparietal metabolism parallels a greater impact of amyloid and anxiety on medial temporal areas in women versus men. <i>Alzheimer's and Dementia</i> , 2020, 16, e044780.	0.4	0
64	Higher CSF STREML2/ β tau ratio levels attenuate effects of polygenic Alzheimer's disease risk on cognitive decline and neurodegeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, e044800.	0.4	0
65	Air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2020, 16, e044802.	0.4	3
66	Multiple pathophysiological biomarkers are associated with gray matter volume and cerebral glucose metabolism in the early preclinical Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044808.	0.4	0
67	APOE ϵ 4 shapes temporo-parietal network properties in middle-aged, cognitively unimpaired individuals: A graph theory analysis. <i>Alzheimer's and Dementia</i> , 2020, 16, e045092.	0.4	0
68	Weight loss predicts Alzheimer's disease biomarker positivity in cognitively unimpaired middle-aged adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e045137.	0.4	0
69	Proximity to parental age at onset exacerbates amyloid burden while mental conditions exacerbate neural loss during midlife. <i>Alzheimer's and Dementia</i> , 2020, 16, e045171.	0.4	0
70	Incidence of subjective cognitive decline is associated with amyloid β pathology, whereas stability relates to neurodegeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, e045293.	0.4	0
71	Amyloid β -positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to hippocampal volume. <i>Alzheimer's and Dementia</i> , 2020, 16, e045715.	0.4	0
72	Impact of APOE ϵ 4 on cerebral amyloid deposition in participants with abnormal soluble amyloid levels. <i>Alzheimer's and Dementia</i> , 2020, 16, e045828.	0.4	1

#	ARTICLE	IF	CITATIONS
73	Cross-modal associations between traditional and emerging CSF biomarkers and grey matter network disruption in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045905.	0.4	0
74	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e047209.	0.4	1
75	Plasma τ 181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e047539.	0.4	2
76	Quantitative informant and self-reports of subjective cognitive decline predict amyloid beta PET outcomes in cognitively unimpaired individuals independently of age and APOE ϵ 4. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12127.	1.2	6
77	Eating a Weekly Serving of Walnuts Relates to Beneficial Brain Imaging Phenotypes in a Cohort at Increased Risk of Alzheimer's Disease. <i>Current Developments in Nutrition</i> , 2020, 4, nzaa057_050.	0.1	2
78	Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, 1358-1371.	0.4	120
79	Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation. <i>Brain</i> , 2020, 143, 976-992.	3.7	16
80	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 265-284.	4.9	121
81	White matter microstructure and cerebrospinal fluid biomarkers of Alzheimer's disease in middle-aged cognitively unimpaired participants (the ALFA study). <i>Alzheimer's and Dementia</i> , 2020, 16, e043027.	0.4	0
82	The <i>MS4A</i> gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	170
83	Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	192
84	Interactive effect of age and APOE ϵ 4 allele load on white matter myelin content in cognitively normal middle-aged subjects. <i>NeuroImage: Clinical</i> , 2019, 24, 101983.	1.4	30
85	Spatial patterns of white matter hyperintensities associated with Alzheimer's disease risk factors in a cognitively healthy middle-aged cohort. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 12.	3.0	46
86	Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 7803.	1.6	33
87	Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 27.	3.0	82
88	Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?. <i>Frontiers in Neurology</i> , 2019, 10, 280.	1.1	87
89	CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals. <i>NeuroImage: Clinical</i> , 2019, 23, 101801.	1.4	26
90	P4573: PROXIMITY TO PARENTAL ONSET AND APOE ϵ 4 INDEPENDENTLY CONTRIBUTE TO AMYLOID BURDEN IN MIDDLE-AGED ADULTS WITH A FAMILY HISTORY OF SPORADIC ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P1539.	0.4	0

#	ARTICLE	IF	CITATIONS
91	O3â€02â€01: APOE<i>â€4</i> ALLELIC LOAD MODULATES THE ASSOCIATION BETWEEN CSF BETAâ€AMYLOID AND GRAY MATTER VOLUME IN COGNITIVELY UNIMPAIRED INDIVIDUALS. Alzheimer's and Dementia, 2019, 15, P877.	0.4	0
92	O3â€11â€01: INFORMANT RATINGS, BUT NOT SELFâ€REPORTS, OF COGNITIVE DECLINE PREDICT AMYLOID PET POSITIVITY IN COGNITIVELY UNIMPAIRED MIDDLEâ€AGED INDIVIDUALS. Alzheimer's and Dementia, 2019, 15, P910.	0.4	0
93	Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. Alzheimer's Research and Therapy, 2019, 11, 94.	3.0	20
94	Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimerâ€™s disease. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641988881.	1.5	46
95	Early increase of CSF sTREM2 in Alzheimerâ€™s disease is associated with tau related-neurodegeneration but not with amyloid-Î² pathology. Molecular Neurodegeneration, 2019, 14, 1.	4.4	253
96	O1â€06â€03: CHARACTERIZATION OF COGNITIVE PERFORMANCE, GRAY MATTER VOLUME AND WHITE MATTER MICROSTRUCTURE IN COGNITIVELY UNIMPAIRED ADULTS WITH INSOMNIA SYMPTOMS. Alzheimer's and Dementia, 2019, 15, .	0.4	1
97	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimerâ€™s disease. Brain, 2018, 141, 1186-1200.	3.7	83
98	Brain and cognitive correlates of subjective cognitive decline-plus features in a population-based cohort. Alzheimer's Research and Therapy, 2018, 10, 123.	3.0	73
99	P1â€137: REDUCED ENTORHINAL GRAY MATTER VOLUME IN HEALTHY AMYLOIDâ€NEGATIVE <i>APOEâ€4</i> HOMOZYGOTES OF THE ALFA COHORT. Alzheimer's and Dementia, 2018, 14, P326.	0.4	0
100	O3â€12â€02: SUBJECTS WITHOUT SELFâ€AWARENESS OF COGNITIVE DECLINE PRESENT DIFFERENT COGNITIVE AND BRAIN MORPHOLOGICAL FEATURES. Alzheimer's and Dementia, 2018, 14, P1050.	0.4	0
101	<sc>CSF</sc> progranulin increases in the course of Alzheimer's disease and is associated with <sc>sTREM</sc> 2, neurodegeneration and cognitive decline. EMBO Molecular Medicine, 2018, 10, .	3.3	64
102	White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimerâ€™s disease. Brain, 2018, 141, 3065-3080.	3.7	116
103	Episodic memory and executive functions in cognitively healthy individuals display distinct neuroanatomical correlates which are differentially modulated by aging. Human Brain Mapping, 2018, 39, 4565-4579.	1.9	32
104	Distinct Cognitive and Brain Morphological Features in Healthy Subjects Unaware of Informant-Reported Cognitive Decline. Journal of Alzheimer's Disease, 2018, 65, 181-191.	1.2	15
105	D04â€...Blood-CSF barrier function and CSF flow influence CSF biomarkers in huntingtonâ€™s disease. , 2018, , .		0
106	The <i>APOE</i> â€4 genotype modulates CSF YKLâ€40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 50-59.	1.2	36
107	CSF sAPPÎ², YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology, 2017, 89, 178-188.	1.5	100
108	The <sc>FTD</sc>â€like syndrome causing <sc>TREM</sc>2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism. EMBO Journal, 2017, 36, 1837-1853.	3.5	152

#	ARTICLE	IF	CITATIONS
109	[P2â€“355]: CSF STREM2, BUT NOT YKLâ€“40, IS ASSOCIATED WITH LONGITUDINAL MORPHOLOGICAL BRAIN CHANGES IN PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P758.	0.4	0
110	[O1â€“02â€“06]: ELEVATED CSF STREM2 IN AUTOSOMAL DOMINANTLY INHERITED ALZHEIMER'S DISEASE ASSOCIATED WITH REGIONAL FIBER TRACT INJURY: RESULTS FROM THE DIAN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P188.	0.4	0
111	Increase of TREM2 during Aging of an Alzheimerâ€™s Disease Mouse Model Is Paralleled by Microglial Activation and Amyloidosis. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 8.	1.7	60
112	<sc>sTREM</sc> 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in earlyâ€“stage Alzheimer's disease and associate with neuronal injury markers. <i>EMBO Molecular Medicine</i> , 2016, 8, 466-476.	3.3	392
113	Early changes in CSF sTREM2 in dominantly inherited Alzheimerâ€™s disease occur after amyloid deposition and neuronal injury. <i>Science Translational Medicine</i> , 2016, 8, 369ra178.	5.8	211
114	ICâ€“Pâ€“15: CSF Levels of Strem2 are Associated With Greater Frontal Cortical Thickness During Advanced Disease Stages in Autosomal Dominant Alzheimer Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P86.	0.4	0
115	F5â€“02â€“04: CSF STREM2 Levels Increase in Early Stages of Autosomal Dominant Alzheimerâ€™s Disease (ADAD) and are Associated with Markers of Neuronal Injury. <i>Alzheimer's and Dementia</i> , 2016, 12, P369.	0.4	0
116	Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 1259-1272.	0.4	86
117	Monomethylated and unmethylated FUS exhibit increased binding to Transportin and distinguish FTLD-FUS from ALS-FUS. <i>Acta Neuropathologica</i> , 2016, 131, 587-604.	3.9	76
118	Early Cerebellar Hypometabolism in Patients With Frontotemporal Dementia Carrying the C9orf72 Expansion. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 353-356.	0.6	8
119	Relationship Between Î²-Secretase, Inflammation and Core Cerebrospinal Fluid Biomarkers for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 157-167.	1.2	106
120	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. <i>Science Translational Medicine</i> , 2014, 6, 243ra86.	5.8	600
121	Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. <i>Human Molecular Genetics</i> , 2014, 23, 749-754.	1.4	98
122	Autosomalâ€“dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter AÎ² production. <i>Journal of Neurochemistry</i> , 2014, 128, 330-339.	2.1	33
123	Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 684-691.	0.9	55
124	Reversal of Neurofibrillary Tangles and Tau-Associated Phenotype in the rTgTauEC Model of Early Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2013, 33, 13300-13311.	1.7	42
125	Endothelial progenitor cells in acute ischemic stroke. <i>Brain and Behavior</i> , 2013, 3, 649-655.	1.0	42
126	Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. <i>Acta Neuropathologica</i> , 2013, 125, 201-213.	3.9	103

#	ARTICLE	IF	CITATIONS
127	Prazosin, an α_1 -adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 1105-1115.	1.5	49
128	Comparison of 2 Diagnostic Criteria for the Behavioral Variant of Frontotemporal Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2013, 28, 469-476.	0.9	10
129	Expansion mutation in C9ORF72 does not influence plasma progranulin levels in frontotemporal dementia. <i>Neurobiology of Aging</i> , 2012, 33, 1851.e17-1851.e19.	1.5	13
130	Propagation of Tau Pathology in a Model of Early Alzheimer's Disease. <i>Neuron</i> , 2012, 73, 685-697.	3.8	1,191
131	Propagation of Tau Pathology in a Model of Early Alzheimer's Disease. <i>Neuron</i> , 2012, 76, 461.	3.8	5
132	Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: results from a case-control study and a meta-analysis. <i>Journal of Neurology</i> , 2012, 259, 111-118.	1.8	41
133	Tau Enhances α -Synuclein Aggregation and Toxicity in Cellular Models of Synucleinopathy. <i>PLoS ONE</i> , 2011, 6, e26609.	1.1	115
134	Dementia Risk in Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 359-64.	4.9	125
135	Pachymeningitis, Painful Ophthalmoplegia, and Multiple Cranial Neuropathy of Presumed Tuberculous Origin. <i>Neuro-Ophthalmology</i> , 2011, 35, 289-292.	0.4	1
136	Polyradiculoneuropathy Associated to Human Herpesvirus 2 in an HIV-1-Infected Patient (Elsberg) <i>Tj ETQq0 0 0 rgBT (Overlock 10 Tf 50</i>	0.8	14
137	PL-05-01: A transgenic model of the earliest stage of Alzheimer's disease. , 2010, 6, S165-S165.		0
138	Tau Phosphorylation and Aggregation as a Therapeutic Target in Tauopathies. <i>CNS and Neurological Disorders - Drug Targets</i> , 2010, 9, 727-740.	0.8	21
139	Blood pressure is not associated with haematoma enlargement in acute intracerebral haemorrhage. <i>European Journal of Neurology</i> , 2008, 15, 1085-1090.	1.7	18
140	ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer. <i>Journal of Neuroimmunology</i> , 2008, 201-202, 163-165.	1.1	46